Meditation Global Market Report 2023 – By Type (Open Monitoring, Focused Attention, Self-Transcending Meditation), By Meditation Type (Zen Meditation, Metta Meditation, Spiritual Meditation Or Transcendental Meditation, Progressive Relaxation Or Body Scan Meditation, Mindfulness Meditation, Breath Awareness Meditation, Kundalini Yoga), By Age (Adult, Children), By End-User (Meditation Centers, Home Setting, Corporates Or Schools Or Colleges) – Market Size, Trends, And Global Forecast 2023-2032

Workplace stress management reduces stress and its negative effects on the mental or physical health of work resources. Stress can be managed using mental, emotional, and behavioural strategies. Workplace stress management helps employees be happier and more positive, assisting in maintaining a strong, healthy workplace culture that is conducive to creativity and productivity. The main service types of workplace stress management are stress assessment, yoga and meditation, resilience training, progress tracking metrics, and other services. The stress assessment is used as a stress test, also called an exercise stress test, to show how your heart works during physical activity. A stress assessment, also known as an exercise stress test, demonstrates how your heart works during physical activity. Stress assessments are important because they help to determine the impact of stressors on employees so that they can be corrected, preventing physical, emotional, or mental distress. The delivery mode for workplace stress management includes individual counsellors, personal fitness trainers, meditation specialists, and other delivery modes. The activities of workplace stress management include indoor and outdoor The end users of workplace stress management are large private organizations, mid-sized private organizations, small private organizations, ngo, and the public sector. The global workplace stress management market market is segmented - 1) By Service: Stress Assessment, Yoga And Meditation, Resilience Training, Progress Tracking Metrics, Other Services 2) By Delivery Mode: Individual Counselors, Personal Fitness Trainers, Meditation Specialists, Other Delivery Modes 3) By Activity: Indoor, Outdoor 4) By End User: Large Private Organizations, Mid-Sized Private Organizations, Small Private Organizations, NGO, Public sector The global workplace stress management market size is expected to grow from $8.64 billion in 2022 to $9.62 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the workplace stress management market is expected to grow to $14.20 billion in 2027 at a CAGR of 10.2%. The increase in the popularity of yoga is expected to propel the growth of the workplace stress management market going forward. Yoga is primarily a spiritual practice that focuses on achieving harmony between the body and mind. It is based on a very delicate science. Yoga promotes mental and physical relaxation, which aids in the reduction of stress and anxiety. Physical postures increase flexibility, relieve tension, and reduce pain. The practice of yoga in professional workplaces is driving the demand for the workplace stress management market. For instance, according to Yoga Basics, a US-based online resource for yoga, about 300 million people practice yoga globally. Therefore, the rising popularity of yoga will fuel the expansion of the market for workplace stress management. Major players in the workplace stress management market are CVS Health Corporation, Fitbit Inc., Asset Health Inc., ComPsych Corporation, CuraLinc Healthcare LLC, Marino Wellness LLC, Wellness Corporate Solutions LLC, Wellsource Inc., Sol Wellness, Central Corporate Wellness Pte. Ltd., and Truworth Wellness. Technological advancements are the key trends in the workplace stress management market. The adoption of advanced solutions is appreciated by organizations that benefit employees to relax their minds and manage their stress. For instance, in April 2022, Talkspace, a US-based digital behavioural technology healthcare company, launched Talkspace Self-Guided, a suite of offerings for employers to help managers, executives, and teams prioritize mental wellness and emotional intelligence in and out of the workplace. This includes a single smartphone app built on the principles of attachment therapy that goes beyond mindfulness exercises that can be accessed anonymously at any time to offer employees tried-and-true mental health training. In January 2021, Google LLC, a US-based technology company, acquired Fitbit for $2.1 billion. With this acquisition, Google wants to improve access to affordable care through an integrated technology network. Fitbit is a US-based consumer-based electronics and fitness company. North America was the largest region in the workplace stress management share market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the workplace stress management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Workplace Stress Management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The workplace stress management market includes revenues earned by entities by meditation, games and fun activities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The workplace stress management market research report is one of a series of new reports from The Business Research Company that provides workplace stress management market statistics, including workplace stress management industry global market size, regional shares, competitors with a workplace stress management market share, detailed workplace stress management market segments, market trends and opportunities, and any further data you may need to thrive in the workplace stress management industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

CBD (Cannabidiol) is a non-psychoactive component derived from the cannabis sativa plant. CBD oil is made by extracting cannabidiol and then diluting it with carrier oil like hemp seed oil or coconut oil. The CBD oils and CBD consumer health are used in dietary supplements for health benefits. The main types of CBD oil and CBD consumer health products are CBD oil, and CBD consumer health. The CBD oil is used for the treatment of many brain-related conditions such as anxiety, depression, epilepsy syndromes, PTSD, and substance addiction. Cannabidiol (CBD) is collected from the cannabis plant and then mixed in oils like hemp seed oil or coconut oil to produce CBD oil. The CBD oil and CBD consumer health products are used in anxiety/stress, sleep/insomnia, chronic pain, migraines, skin care, seizures, joint pain and inflammation, neurological conditions, and other applications. The CBD oil and CBD consumer health products are distributed through different channels including CBD oil (B2B and B2C) and CBD consumer health (online, retail stores, and retail pharmacies). The global CBD oil and CBD consumer health market is segmented - 1) By Product: CBD Oil, CBD Consumer Health 2) By Application: Anxiety/Stress, Sleep/Insomnia, Chronic Pain, Migraines, Skin Care, Seizures, Joint Pain And Inflammation, Neurological Conditions, Other Applications 3) By Distribution Channel: CBD Oil (B2B and B2C), CBD Consumer Health (Online, Retail Stores, and Retail Pharmacies) The global CBD oil and CBD consumer health market size is expected to grow from $39.54 billion in 2022 to $49.72 billion in 2023 at a compound annual growth rate (CAGR) of 25.75%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the CBD oil & CBD consumer health market is expected to reach $123.91 billion in 2027 at a CAGR of 25.64%. Increasing awareness regarding the health benefits of CBD-infused products is driving the CBD oils and CBD consumer health market. CBD-infused products include food and personal care products with CBD as an ingredient. People are becoming more aware of the health benefits of CBD-infused products, which results in more use of cannabidiol products. People use CBD oil to treat sleep problems, anxiety, pain, stress, and discomfort. For instance, in 2020, according to a survey conducted by SingleCare, a US-based authorized prescription discount plan organization, 33% of Americans have already used CBD, while 64% of current CBD users were using CBD for pain relief and inflammation. Besides, 45% of the current CBD users increased their CBD use after the COVID-19 pandemic. As a result, the increasing awareness regarding the health benefits of CBD-infused products is propelling the CBD oils and CBD consumer health market. Major players in the CBD oil and CBD consumer health market are CVSciences Inc., Endoca BV, Isodiol International Inc., Elixinol LLC, NuLeaf Naturals LLC, JOY Organics, Lord Jones, Canopy Growth Corporation, CBD American Shaman, BioVectra Inc., Bluebird Botanicals, Noramco Inc., and Cibdol B.V. Technological advancement is a key trend in the CBD oils and CBD consumer health market. Major companies in the market are introducing technologically innovative products to remain competitive in the market. For instance, NextEvo Naturals, a US-based premium supplement brand, launched NextEvo premium pure cannabidiol (CBD) gummies with hemp extract that contains 10 mg of its SmartSorb CBD. It is vegan, non-GMO, and THC-free. These gummies offer rapid and enhanced absorption due to SmartSorb delivery technology that turns oil-soluble CBD into a water-soluble-like emulsion. In February 2022, Flora Growth Corp., a Canada-based cannabis products manufacturer, acquired JustCBD for an undisclosed amount. The acquisition will strengthen Flora’s footprint in the U.S. wellness market and provide global expansion opportunities for Flora’s product lines. JustCBD is a US-based manufacturer of CBD-infused products. North America was the largest region in the CBD oil and CBD consumer health market share in 2022. The regions covered in the CBD oil and CBD consumer health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the CBD oil and CBD consumer health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The CBD oils and CBD consumer health market consists of sales of CBD isolate and synthetic CBD. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The CBD oil and CBD consumer health products market research report is one of a series of new reports from The Business Research Company that provides CBD oil and CBD consumer health products market statistics, including CBD oil and CBD consumer health products industry global market size, regional shares, competitors with a CBD oil and CBD consumer health products market share, detailed CBD oil and CBD consumer health products market segments, market trends and opportunities, and any further data you may need to thrive in the CBD oil and CBD consumer health products industry. This CBD oil and CBD consumer health products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Post-traumatic stress disorder therapeutics refers to therapeutics used to treat post-traumatic stress disorder (PTSD), a mental health condition triggered by either experiencing it or witnessing it. Post-traumatic stress disorder treatment helps to improve patients thinking power, changes in physical activity & regain a sense of control over life. The mode of treatment applied for post-traumatic stress disorder includes medication, therapies, self-care & nutrition. The main drugs in post-traumatic stress disorder therapeutics include antidepressants, anti-anxiety, antihypertensive, monoamine oxidase (MAOS), antipsychotics or second-generation antipsychotics (SGOS), beta-blockers, others (benzodiazepines and others). Antidepressants refer to a class of drugs that are used to manage addictions and treat illnesses like major depressive disorder, anxiety disorders, and chronic pain. The age group receiving the therapeutics includes pediatric, geriatric, and adults, by various end users including mental health centers, hospitals, outpatient clinics, and others. The global post-traumatic stress disorder therapeutics market is segmented - 1) By Drug Class: Antidepressants, Anti-Anxiety, Antihypertensive, Monoamine Oxidase (MAOs), Antipsychotics Or Second Generation Antipsychotics (SGOs), Beta-Blockers, Other Classes 2) By Age Group: Pediatric, Geriatric, Adult 3) By End User: Mental Health Center, Hospitals, Outpatient Clinics, Other End Users The global post-traumatic stress disorder therapeutics market size is expected to grow from $3.15 billion in 2022 to $3.42 billion in 2023 at a compound annual growth rate (CAGR) of 8.72%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The post-traumatic stress disorder therapeutics market size is expected to reach $4.82 billion in 2027 at a CAGR of 8.96%. The rise in the burden of post-traumatic stress disorder (PTSD) cases across the globe are expected to propel the growth of the post-traumatic stress disorder therapeutics market going forward. Post-traumatic stress disorder refers to a disorder that develops in people who have experienced a scary, shocking, or dangerous event. Post-traumatic stress disorder treatment such as psychotherapy and medication can help to regain a sense of control over their life. For instance, according to the United States Department of Veterans Affairs, a US-based government department, Nearly 8 million Americans are suffering from PTSD condition in 2021. Hence the rise in the burden of post-traumatic stress disorder (PTSD) cases is driving the growth of the post-traumatic stress disorder therapeutics market. Strategic collaborations, funding, and investments have emerged as a key trend gaining popularity in the post-traumatic stress disorder therapeutics market. Major companies operating in the market are developing strategic collaborations and investing in the companies to strengthen their position in the market. For instance, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University, members of an interdisciplinary research team were given over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD). The initiative is one of seven clinical studies under the Medical Research Future Fund (MRFF) unveiled this month by the Federal government to evaluate the use of potentially ground-breaking combination medicines to treat crippling mental diseases. In October 2020, Jazz Pharmaceuticals Ireland Limited, an Ireland-based biopharmaceutical company acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program, including PF-04457845 for an undisclosed amount. Through this acquisition, Jazz will first concentrate on creating PF-04457845 in order to research its potential for treating post-traumatic stress disorder ("PTSD") and its symptoms. SpringWorks is a US-based clinical-stage biopharmaceutical company. Major players in the post-traumatic stress disorder therapeutics market are Novartis AG, Pfizer Inc., Bionomics Ltd., Apotex Inc., GlaxoSmithKline PLC., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Pvt Ltd., Strategic Behavioral Health, Jazz Pharmaceuticals, Bionomics, Behavioral Health Network Inc., AstraZeneca PLC., Apotex Inc., Prometheon Pharma LLC., Ligand Pharmaceuticals Incorporated, Lycera Corp. and JSC Valenta Pharm. North America was the largest region in the post-traumatic stress disorder therapeutics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the post-traumatic stress disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The post-traumatic stress disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed sulfuric acid market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This sulfuric acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Non-alcoholic steatohepatitis (NASH) is a type of liver inflammation and damage caused by a build-up of fat in the liver. NASH biomarkers are used as diagnostic tools to assess the severity of non-alcoholic steatohepatitis and to assess liver damage. This damages the liver cells and inflames the liver, which can result in cirrhosis (liver scarring) and liver failure. Biomarkers refer to a particular quality that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment. The main types of non-alcoholic steatohepatitis biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers and others. Hepatic fibrosis biomarkers refer to biomarkers for hepatic fibrosis, an overly exuberant wound healing in which excessive connective tissue develops in the liver. They are used to treat different diseases including hypertension, heart disease, high blood lipid, type 2 diabetes and obesity for use by various end-uses such as research institutes and academics, diagnostic centres, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics and others.. The global non-alcoholic steatohepatitis biomarkers market is segmented - 1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types 2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity 3) By End Use: Research Institutes And Academics, Diagnostic Centres, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses The global non-alcoholic steatohepatitis biomarkers market size is expected to grow from $0.88 billion in 2022 to $1.10 billion in 2023 at a compound annual growth rate (CAGR) of 24.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global non-alcoholic steatohepatitis biomarkers market size is expected to grow to $2.54 billion in 2027 at a CAGR of 23.2%. The growing prevalence of non-alcoholic steatohepatitis (NASH) is expected to boost the growth of the non-alcoholic steatohepatitis biomarkers market going forward. Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by severe liver inflammation. The prevalence of NASH diseases is increasing due to the increasing number of overweight and obese patients. The non-alcoholic steatohepatitis biomarkers are used to diagnose and help better treat patients with NASH. For instance, in September 2020, according to “The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective,” an article published by The American Journal of Medicine, a US-based peer-reviewed medical journal and the official journal of the Alliance for Academic Internal Medicine, the number of Americans who have non-alcoholic fatty liver disease will rise from 83.1 million in 2015 to 100.9 million in 2030. By 2030, It is anticipated that the incidence of non-alcoholic steatohepatitis (NASH), decompensated cirrhosis, and hepatocellular carcinoma will rise by 63%, 168%, and 137%, respectively. Non-alcoholic steatohepatitis (NASH) can progress from non-alcoholic fatty liver disease (NAFLD). Therefore, the growing prevalence of non-alcoholic steatohepatitis (NASH) is driving the growth of the non-alcoholic steatohepatitis biomarkers market. Major players in the non-alcoholic steatohepatitis biomarkers market are Genfit, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, and Allergan PLC. Technological advancements are a key trend in gaining popularity in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are focused on developing innovative solutions to strengthen their position in the market. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, agreed on a five-year exclusive licensing deal for GENFIT's NIS4 technology to aid in identifying patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically developed to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also referred to as at-risk NASH. As part of the agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada, giving widespread access to healthcare professionals. In June 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company partnered with Echosens SA. With this partnership, the companies intend to promote non-alcoholic steatohepatitis (NASH) early diagnosis and raise disease awareness among patients, medical professionals, and other stakeholders. Echosens SA is a France-based manufacturer of therapeutic monitoring and diagnostic devices. North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2022. Asia-Pacific is expected to be the fastest-growing region in the global non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the global non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antiemetics and antinauseants refer to drugs that are used in the prophylaxis or management of vomiting that results from emetogenic chemotherapy, and for the management of postoperative nausea and vomiting. Antiemetic and antinauseant drugs prevent, control, or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu, or chemotherapy. These drugs reduced the symptoms of nausea or vomiting by blocking signal messages to the part of the brain that controls nausea and vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonists, antihistamines (h1 histamine receptor antagonists), cannabinoids, and benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists, and others. A dopamine antagonist also referred to as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, and others and is implemented in various sectors such as hospitals, medical centers, clinics, and research institutes. The global antiemetics and antinauseants market is segmented – 1) By Drug: Dopamine antagonists, NK1 receptor antagonist, Antihistamines (H1 histamine receptor antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 receptor antagonists, Other Drug Types 2) By Application: Chemotherapy, Motion sickness, Gastroenteritis, General anaesthetics, Opioid analgesics, Dizziness, Pregnancy, Food poisoning, Emotional stress, Other Application Types 3) By End Users: Hospital, Medical Center, Clinic, Research Institutes The global antiemetics and antinauseants market size will grow from $7.76 billion in 2022 to $8.09 billion in 2023 at a compound annual growth rate (CAGR) of 4.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antiemetics and antinauseants is expected to grow to $9.12 billion in 2027 at a CAGR of 3.0%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatments to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by the Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac), and other serotonin 5-HT3 receptor types of antagonists. An increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for the market. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb, and SRS Pharmaceuticals . Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the antiemetics and antinauseants market. Despite the presence of a range of drugs, the practitioners prescribe similar drugs to treat patients with different conditions of nausea. The popularity of only a few drugs leads to lower demand for other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kinds of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specifically targeted sites in a controlled manner through Nanomedicine and Nano delivery systems. Nanomedicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures, and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drug manufacturers are inclining more toward the use of Nanomedicine or Nano drugs to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is the first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of the Food and Drug Administration Department of Health and Human Services, U.S. part 336, contains conditions that all Antiemetic and Antinauseant drugs are required to fulfil to remain in the market, such as definitions, regulations, and regulations related to the labelling of the antiemetic drug products. North America was the largest region in the drugs for antiemetics and antinauseants market in 2022. The Middle East is expected to be the fastest-growing region in the global antiemetics and antinauseants market share. The regions covered in the global antiemetics and antinauseants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimetics and antinauseants market consists of sales of dopamine, serotonin, neurokinin, histamine, and acetylcholine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antiemetics and antinauseants market research report are one of a series of new reports from The Business Research Company that provides antiemetics and antinauseants market statistics, including antiemetics and antinauseants industry global market size, regional shares, competitors with antiemetics and antinauseants market share, detailed antiemetics and antinauseants market segments, market trends and opportunities, and any further data you may need to thrive in the antiemetics and antinauseants industry. This antiemetics and antinauseants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Psychedelic drug refers to a group of psychoactive drugs that alter perception, mood, and thought processes. All of the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. These include chemicals such as Lysergic acid diethylamid (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions. The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The global psychedelic drugs market is segmented - 1) By Type: Lysergic Acid Diethylamid (LSD), Ketamine, Phencyclidine, Gamma Hydroxybutyric Acid (GHB), Salvia 2) By Disease Indication: Depression, PTSD 3) By Origin: Natural, Synthetic 4) By Application: Treatment-Resistant Depression, Opiate addiction, Post- Traumatic Stress Disorder, Narcolepsy, Panic Disorders 5) By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy The global psychedelic drugs market size will grow from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the psychedelic drugs is expected to grow to $8.31 billion in 2027 at a CAGR of 14.5%. The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drugs market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drugs market. Major players in the psychedelic drugs market are Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc., Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc., AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Allergan Inc., Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG. The introduction of "depression spray" is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal spray drugs for major depressive disorders to sustain their position in the market. For instance, in August 2021, Hikma Pharmaceuticals plc, a UK based pharmaceutical company, launched KLOXXADO. KLOXXADO is an 8 mg nasal spray containing naloxone HCl. This spray is used for the immediate care of patients, both adults and children, with known or suspected opioid overdoses, as shown by respiratory depression and/or central nervous system depression. In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine. North America was the largest region in the psychedelic drugs market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psychedelic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drugs market statistics, including psychedelic drugs industry global market size, regional shares, competitors with a psychedelic drugs market share, detailed psychedelic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aromatherapy refers to devices which utilize essential oils extracted from nature, such as plants, either to be inhaled or applied to the body to promote health and well-being. The aroma molecules in essential oils move straight from the olfactory nerves to the brain when inhaled, and affecting the amygdala, the brain's emotional center. Aromatherapy helps in reducing pain, enhances sleep quality, reduces joint pain, reduces stress, and others. The main types of aromatherapy products include equipment and consumables. Aromatherapy equipment refers to electronic or non-electronic device, that breaks down essential oil into molecules and disperses them into air in the form of tiny breathable particles. They are delivered through topical application, areal diffusion, and direct inhalation. They are used for relaxation, skin & hair care, pain management, cold & cough, scar management, insomnia, and others. They are sold through B2B and DTC channels to customers from home use, sap & wellness centers, hospitals & clinics, yoga & meditation centers. The global aromatherapy market is segmented - 1) By Product Type: Consumables, Equipment 2) By Delivery Outlook: Topical Application, Aerial Diffusion, Direct Inhalation 3) By Application: Relaxation, Skin & Hair Care, Pain Management, Cold & Cough, Insomnia, Scar Management, Other Applications 4) By End-Use: Home Use, Spa & Wellness Centers, Hospitals & Clinics, Yoga & Meditation Centers 5) By Distribution Channel: D2C, B2B The global aromatherapy market size grew from $1.77 billion in 2022 to $1.93 billion in 2023 at a compound annual growth rate (CAGR) of 9.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The aromatherapy market size is expected to grow to $2.75 billion in 2027 at a CAGR of 9.2%. Rising stress, anxiety, and depression among people is driving the growth of the aromatherapy market. The COVID-19 pandemic has caused numerous changes in individual lives, including uncertainty, disrupted daily routines, financial strains, and social isolation, leading to increased tension, worry, and sadness. The individuals are looking out for ayurvedic and chemical free methods such as aromatherapy to reduce, anxiety and depression. According to a scientific brief issued today by the World Health Organization (WHO) in March 2022, the global occurrence of anxiety and sadness soared by a staggering 25% in the first year of the COVID-19 pandemic. Therefore, the rising stress, anxiety, and depression among people is expected to boost demand for aromatherapy during forecast period. Major players in the aromatherapy market are doTERRA, Young Living Essential Oils, Edens Garden, Mountain Rose Herbs, Plant Therapy Essential Oils, Rocky Mountain Oils, LLC, Florihana, Falcon, Biolandes, Stadler Form Aktiengesellschaft, Hubmar International, SpaRoom, Now foods, Zija international, and Nu skin. Product innovation is a key trend gaining popularity in the aromatherapy market. The companies are focusing on developing innovative equipment and consumables with greater effectiveness to meet the customer demand and strengthen their business reach. One of the recent developments in aromatherapy is usage of CBD in aromatherapy and diffusers. CBD oil is similar to essential oils, made from the direct extraction of oil from the cannabis plant. It has the potential to provide an even higher degree of treatment, hence extending the therapeutic advantages of essential oils. Adding CBD to the mix produces a whole new level of medicinal value that can be much more soothing, has more profound stress relief, and can help control symptoms like inflammation and pain. In January 2022, Martha Stewart CBD, a brand operated by Canopy Growth, a USA-based provider of cannabis and cannabis-based consumer products, lunched new line of products sleep science CBD cream and Daily De-Stress CBD cream with aroma technology. In January 2022, Mensa Brands, an India-based company specializing in fashion and apparel, home and garden, beauty, and personal care, acquired Florona for an undisclosed amount. This acquisition will help them create a line of aromatherapy bath products and natural skincare and haircare solutions, expand their footprint into new areas, and build a tech-driven global supply chain. Florona is personal care brand involved in providing aromatherapy and natural personal care products. Florona offers over 70 different kinds of natural oils, including diffuser essential oils and cold-pressed carrier oils. Western Europe was the largest region in the aromatherapy market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aromatherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aromatherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The aromatherapy market consists of revenues earned by entities by providing cosmetic aromatherapy, medical aromatherapy and massage aromatherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The aromatherapy market research report is one of a series of new reports from The Business Research Company that provides aromatherapy market statistics, including aromatherapy industry global market size, regional shares, competitors with an aromatherapy market share, detailed aromatherapy market segments, market trends and opportunities, and any further data you may need to thrive in the aromatherapy industry. This aromatherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Mental health apps refer to mobile and PC-based applications used by people to manage their mental health. These apps help people to manage their medications and help in reducing stress and monitoring symptoms of disorders. The user can get therapies virtually for conditions such as PTSD, psychotic disorders, anxiety disorders, and others. The main platforms used in mental health apps include IOS, Android, and others. The iOS mental health apps refer to mental health and wellness used in iOS-enabled mobile phones or tablets. IOS is an operating system developed by Apple Inc., for mobile devices. These applications are used for depression and anxiety management, meditation management, stress management, wellness management, and others. The global mental health apps market is segmented - 1) By Platform Type: iOS, Android, Other Platform Types 2) By Application Type: Depression and Anxiety management, Meditation Management, Stress Management, Wellness Management, Other Application Types The global mental health apps market size will grow from $5.49 billion in 2022 to $6.36 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of thr mental health apps is expected to grow to $11.62 billion in 2027 at a CAGR of 16.3%. The increasing awareness about mental health and its significance is propelling the growth of the mental health apps market. Increasing openness about mental health by sports personalities and celebrities has reduced the stigma and increased awareness about mental health and its importance on one’s health across the globe. Additionally, individuals with mental health-related problems are investing in various recovery therapies such as medical consultations, mental health apps, self-help books, and others. For instance, according to the study published by National Alliance for Mental Illness, in 2020, more than 21% of USA adults experienced mental illness, and more than 26.3 million adults received virtual mental health services. Therefore, the increasing awareness of mental health and its awareness drive the mental health app market growth. Major players in the mental health apps market are Mindscape, Calm, MoodMission, Headspace, Flow Neurosciences, Youper, Happify, Sanvello, NOCD, Talkspace, Addicaid, Silvercloud Health, Moodfit, BetterHelp, and eMoods. Technological advancement is a key trend gaining popularity in the mental health apps market. Major companies operating in the mental health apps market are focused on providing technologically-advanced solutions to meet end-customer demands and strengthen their market position. These companies are implementing next-generation technologies into their services, such as CRM, video API, text API, and end-to-end patient engagement through AI and ML and others. For instance, In January 2021, Moody, a health care company, launched an intelligent mental health care app that can identify and alert the user about psychological changes in their behaviour ahead of time and recommend corrective actions daily. It allows the user to create daily journal entries with memories such as pictures, attachments, and others. In January 2021, Headspace Health, a UK-based provider of digital mental health and wellbeing solutions, acquired Sayana for an undisclosed amount. Through this acquisition, Headspace is focused on integrating AI capabilities into its systems, providing better mental health services to customers and personalized user experiences. Sayana is an India-based provider of AI-powered mental health and wellness solutions. North America was the largest region in the mental health apps market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mental health apps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the mental health apps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The mental health apps market includes revenues earned by entities by providing services such as self-awareness by controlling their mood, maintaining good habits and breaking bad ones, and cultivating positive thinking. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The mental health apps market research report is one of a series of new reports from The Business Research Company that provides mental health apps market statistics, including mental health apps industry global market size, regional shares, competitors with a mental health apps market share, detailed mental health apps market segments, market trends and opportunities, and any further data you may need to thrive in the mental health apps industry. This mental health apps market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.